Biogen stock: buy or sell?
September 20th, 2019
Biogen Inc. discovers, develops, manufactures, and delivers therapies for the treatment of neurological and neurodegenerative diseases worldwide.
Should I buy Biogen stock?Make a decision about when to buy or sell stocks is one of the hardest parts of being a trader or investor. That's why is so important to define your own trading strategy that matches with your character as inversor. At Stocks2.com, we like to use very simple but trusted and powerful trend following trading strategies. Simple things usually work the best.
None of our preferred buy setups matches with Biogen stock situation right now, hence this is not a suitable entry point.
|New all-time high||No|
|New 52 week high||No|
|Price crossing up 200d MA||No|
|100d MA crossing up 200d MA||No|
Is Biogen stock a buy?
Everyday, hundreds of stock ratings are published by financial analysts to indicate a particular stock's attractiveness.At Stocks2.com, we collected 15 ratings published for BIIB stock in the last month.
|Date||Analyst / Broker||Previous rating||Current rating|
|2019-6-28||Piper Jaffray Companies||Overweight||Neutral|
|2019-4-24||JPMorgan Chase & Co.||n/a||Hold|
|2019-4-10||Raymond James||n/a||Market Perform|
|2019-3-25||Royal Bank of Canada||n/a||Sector Perform|
Biogen stock analysis
Shares of Biogen ended today at $238.79 and grew a nice 1.35%.
Biogen shares grew 1.35% to $238.79 today. Since Sep/10 when BIIB stock price broke up the SMA100d line, it gained $8.79 (3.82%). Since SMA50d and SMA100d crossed up on Aug/9, BIIB price climbed $0.56 per share (0.24%).
After boosting a phenomenal 5.10% in a week last week, Biogen closed this week at $238.79 and gained a tiny 0.91%. With this, it's been 3 green weeks in a row, gaining $19.04 or 8.43%.
Since price and 40-weeks moving average lines crossed down by mid March, BIIB fell $-91.08 per share (-27.61%). Trading stocks that are below the 40-weeks (that is, 200-days) moving average mark is not recommended by many experts, as it indicates that the stock has not enough institutional support.
Biogen stock price history
Biogen stock went public on September 17th, 1991 with a price of $3.001. Since then, BIIB stock grew a 7,859.70%, with a yearly average of 280.70%. If you had invested right after BIIB's IPO a $1,000 in Biogen stock in 1991, it would worth $78,597.00 today.
1: Adjusted price after possible price splits or reverse-splits.
Biogen stock historical price chart
BIIB stock reached 52-week highs on October at $358.41, and all-time highs 2015-03-20 with a price of 480.18.
Biogen stock price target is $268.40Nobody can reliably foresee how stock prices may evolve in the future. However, financial institutions invest time and resources to provide the most accurated estimations to help investors to make their decisions. We do not recommend to follow these stock price predictions without a critical thinking from your side, as their accuracy is usually low. For the last 30 days we found 8 price predictions for Biogen stock:
|Date||Analyst / Broker||Action||Previous target||Current target||Diff|
|2019-7-24||Canaccord Genuity||Raises Target||$275.00||$285.00||3.6%|
|2019-3-25||Royal Bank of Canada||Lowers Target||n/a||$236.00||-|
|2019-3-25||HC Wainwright||Lowers Target||$363.00||$300.00||-17.4%|
|2019-3-22||Guggenheim||Set Price Target||n/a||$236.00||-|
Financials and fundamental analysis
Earnings date and Earnings per ShareSince April, when Biogen presented its last earnings report, it . As soon as we get its posted EPS from the earnings report, we will update this review.
|Quarter||Reporting date||Estimated EPS||Actual EPS||Surprise|
Annual financial resultsCompared to 2017, last anual revenues report draw a phenomenal increase of 9.61% to $13,452.90 M USD. When comparing 2018 vs 2017, aligned with this, profit margin (that is, the net income divided by revenues) boosted a 12.25% to 32.93%. Biogen fiscal year ends in December, and to compare its evolution since then, we estimate annual sales and income figures by adding results from the last 4 quarters. This is called TTM (or Twelve Trailing Months). So, Biogen TTM sales up to March 2019 were $13,811.60 and income $4,666.60 million dollars. If we compare this TTM figures with the last reported annuality, we can esteem Biogen business evolution since December 2018: Annual turnover up to March, compared to lastest yearly report, grew a tiny 2.67%. Regarding profit margin, Biogen stayed stable 0.85% to 32.93%
|2013||$5,860 M||-||$1,860 M31.7%||-|
|2014||$9,703 M||65.59%||$2,935 M30.2%||57.78%|
|2015||$10,764 M||10.93%||$3,547 M33.0%||20.86%|
|2016||$11,449 M||6.36%||$3,703 M32.3%||4.39%|
|2017||$12,274 M||7.21%||$2,539 M20.7%||-31.43%|
|2018||$13,453 M||9.61%||$4,431 M32.9%||74.50%|
|TTM||$13,812 M||2.67%||$4,667 M33.8%||5.32%|
Quarterly financial resultsBiogen posted $3,489.80 million in revenues for 2019-Q1, a -1.04% decline compared to previous quarter. Reported quarter earnings marked $1,408.80 M with a profit margin of 40.37%. Profit margin rocketed a 13.52% compared to previous quarter when profit margin was 26.85%. When comparing revenues to same quarter last year, Biogen sales marked a cool growth and climbed a 11.46%.
|2017-Q2||$2,730 M||-||$863 M31.6%||-|
|2017-Q3||$2,770 M||1.47%||$1,230 M44.4%||42.56%|
|2017-Q4||$3,307 M||19.39%||$-297 M-9.0%||-124.18%|
|2018-Q1||$3,131 M||-5.32%||$1,173 M37.5%||-494.38%|
|2018-Q2||$3,357 M||7.20%||$867 M25.8%||-26.11%|
|2018-Q3||$3,439 M||2.46%||$1,444 M42.0%||66.67%|
|2018-Q4||$3,526 M||2.54%||$947 M26.8%||-34.45%|
|2019-Q1||$3,490 M||-1.04%||$1,409 M40.4%||48.80%|
Biogen ownershipWhen you are planning to buy shares of a company, it's worth to check its ownership structure.
Biogen shares owned by insiders (that is, founders, CEO, CTO, main executives or other management staff) currently counts a 0.47% of all shares.
Bearish positions for BIIB stock account 0.00%, no big difference from last month.
The following table compares ownership indicators for other stocks related to Biogen:
|Market cap||$44.0 B||$106.1 B||$167.9 M||$118.1 B||$8.4 B|
|Total shares||184.5 M||1,480.0 M||48.1 M||599.7 M||24.7 M|
|Float shares||184.0 M||1,480.0 M||39.5 M||598.3 M||21.3 M|
|- Institutional holdings (%)||93.4%||71.9%||112.3%||81.9%||78.0%|
|- Insider holdings (%)||0.5%||0.1%||1.8%||0.2%||14.6%|
|Shares in short selling||0.0%||0.0%||0.0%||0.0%||0.0%|
|Friday, September 20th, 2019|
|Day range||$234.31 - $242.21|
|Average true range||$5.99|
|50d mov avg||$232.47|
|100d mov avg||$231.67|
|200d mov avg||$263.76|
Biogen performancePerformance as an absolute value is never valid if it's not benchmarked against competitors or related stocks in the industry. For Biogen, the benchmark is made against AbbVie, Acorda Therapeutics, Amgen, Bio-Rad Laboratories, Celgene, Gilead Sciences, , Pfizer, Sangamo Therapeutics and .
Biogen competitorsOne check before investing in any stock is to have a look a list of its competitors, in this case for Biogen. We selected 10 companies as Biogen competitors as they are in the same industry or have similar market objectives.
- AbbVie (ABBV)
- Acorda Therapeutics (ACOR)
- Amgen (AMGN)
- Bio-Rad Laboratories (BIO)
- Celgene (CELG)
- Gilead Sciences (GILD)
- Pfizer (PFE)
- Sangamo Therapeutics (SGMO)
Latest Biogen stock news
- InvestorPlaceBiogen Earnings: BIIB Stock Surges on Big Q2 Earnings BeatJuly 23, 2019
- InvestorPlaceMS Franchise, Spinraza Likely to Be Key Catalysts for Biogen StockJuly 22, 2019
- Seeking AlphaRent-A-Gene With Biogen's Spinraza, Or Buy-A-Gene With Novartis' ZolgensmaMay 28, 2019
- Seeking AlphaBiogen's ALS Treatment Is Exciting, But Market Is MicroscopicMay 3, 2019
- Seeking AlphaWhy Biogen Could Be A Buy At These LevelsApril 29, 2019